Dataset Information

SChLAP1 pulldown, Hargrove Lab Duke University

ABSTRACT: Test v Control IP of SChLAP1 analyzed by bottoms-up proteomics approach on Orbitrap Astral.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Erik Soderblom

LAB HEAD: Amanda Hargrove,

PROVIDER: PXD055741 | Pride | 2025-09-08

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20240621_073009_10492_james_062124_Report_peptide.tsv	Tabular
	ID114158_01_SPD30_OA10034_10492_061824.raw	Raw
	ID114159_01_SPD30_OA10034_10492_061824.raw	Raw
	ID114160_01_SPD30_OA10034_10492_061824.raw	Raw
	ID114161_01_SPD30_OA10034_10492_061824.raw	Raw

Items per page:

1 - 5 of 5

Publications

Structural analysis of the lncRNA SChLAP1 reveals protein binding interfaces and a conformationally heterogenous retroviral insertion.

Falese James P JP McFadden Emily J EJ D'Inzeo Christopher A CA Hargrove Amanda E AE

RNA (New York, N.Y.) 20250818 9

The lncRNA second chromosome locus associated with prostate 1 (SChLAP1) was previously identified as a predictive biomarker and potential driver of aggressive prostate cancer. Recent work suggested that SChLAP1 may bind the SWI/SNF chromatin remodeling complex to promote prostate cancer metastasis, though the exact role of SWI/SNF recognition is debated. To date, there are no detailed biochemical studies of <i>apo</i> SChLAP1 or SChLAP1:protein complexes. Herein, we report the first secondary st ...[more]

PMID: 40500149

Similar Datasets

Project description:Liposomal amphotericin B is an important frontline drug for the treatment of visceral leishmaniasis, a neglected disease of poverty. The mechanism of action of amphotericin B (AmB) is thought to involve interaction with ergosterol and other ergostane sterols, resulting in disruption of the integrity and key functions of the plasma membrane. Emergence of clinically refractory isolates of L. donovani and L. infantum is an ongoing issue and knowledge of potential resistance mechanisms can help to alleviate this problem. Here we report the characterisation of four independently selected L. donovani clones that are resistant to AmB. Whole genome sequencing revealed that in three of the moderately resistant clones, resistance was due solely to the deletion of a gene encoding C24-sterol methyltransferase (SMT1). The fourth, hyper-resistant resistant clone (>60-fold) was found to have a 24 bp deletion in both alleles of a gene encoding a putative cytochrome P450 reductase (P450R1). Metabolic profiling indicated these parasites were virtually devoid of ergosterol (0.2% versus 18% of total sterols in wild-type) and had a marked accumulation of 14-methylfecosterol (75% versus 0.1% of total sterols in wild-type) and other 14-alpha methylcholestanes. These are substrates for sterol 14-alpha demethylase (CYP51) suggesting that this enzyme is a bona fide P450R specifically involved in electron transfer from NADPH to CYP51 during catalysis. Deletion of P450R1 in wild-type cells phenocopied the metabolic changes observed in our AmB hyper-resistant clone as well as in CYP51 nulls. Likewise, addition of a wild type P450R1 gene restored sterol profiles to wild type. Our studies indicate that P450R1 is essential for L. donovani amastigote viability, thus loss of this gene is unlikely to be a driver of clinical resistance. Nevertheless, investigating the mechanisms underpinning AmB resistance in these cells provided insights that refine our understanding of the L. donovani sterol biosynthetic pathway.